Investors

Corporate Profile

Aeglea is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer. The company’s engineered human enzymes modulate the extremes of amino acid metabolism in the blood to reduce toxic levels of amino acids in inborn errors of metabolism or target tumor metabolism for cancer treatment. AEB1102, Aeglea’s lead product candidate, is currently being studied in two ongoing Phase 1 clinical trials in patients with advanced solid tumors and acute myeloid leukemia/myelodysplastic syndrome (AML/MDS). Additionally, Aeglea is recruiting patients into its Phase 1/2 trial of AEB1102 for the treatment of patients with Arginase I deficiency. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocystine, a target for an inborn error of metabolism, as well as two potential treatments for cancer, AEB3103, which degrades cysteine/cystine, and AEB2109, which degrades methionine.

Stock Information

AGLE (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$4.86
Change (%) Stock is Up 0.13 (2.75%)
Volume28,452
As of 09/22/17 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: AGLE.O.  Currently trading at $4.86 with a 52 week high of $10.34 and a 52 week low of $2.81.

Recent News

More >>
09/06/17

Aeglea BioTherapeutics Doses Two Patients in Repeat Dose Part of Phase 1/2 Clinical Trial for the Treatment of Arginase 1 Deficiency

Topline data is expected in second half of 2018 AUSTIN, Texas, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid meta

Read More

08/31/17

Aeglea BioTherapeutics to Present at the 2017 Wells Fargo Healthcare Conference

AUSTIN, Texas, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer,

Read More

08/09/17

Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2017 Financial Results

AUSTIN, Texas, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer,

Read More

Upcoming Events

More >>
There are currently no events scheduled.